Treatment of chronic heart failure with a low ejection fraction with sacubitril/valsartan (savesto) on the background of diabetes mellitus type 2

Файзуллаев Бахром Рустамович, Исломов Иномжон Исломович, Хусаинов Адхам Шухратович, Норматова Умида Юлдашевна

Марказий Осиё эндокринологик журнали · 2026-yil

Annotatsiya

Relevance. This article analyzes the process of treating patients with CHF and CHF with a low ejection fraction against the background of type 2 diabetes mellitus. Heart failure with reduced ejection fraction (HFrEF) remains one of the most significant medical and social problems, particularly when combined with type 2 diabetes mellitus (T2DM). In 2016, the original angiotensin receptor–neprilysin inhibitor (ARNI), sacubitril/valsartan, was introduced under the trade name Yuperio and demonstrated a convincing reduction in hospitalizations and mortality among this patient population. Subsequently, a generic version — Savesto — became available, containing the same combination of neprilysin inhibitor and angiotensin II receptor blocker. The purpose of this study was to evaluate whether Savesto (szcubitril/valsartan) is non-inferior in terms of efficacy and safety in patients with HFrEF and T2DM, including those who were switched from the branded medication. Materials and methods. A total of 57 patients hospitalized with chronic heart failure and acute decompensation on the background of T2DM were enrolled. Treatment with Savesto resulted in clinical improvement, reduction in NYHA functional class, decrease in NT-proBNP levels, favorable dynamics of laboratory parameters, and positive echocardiographic changes. Although some patients experienced symptomatic arterial hypotension and a decline in eGFR, overall tolerability was acceptable, and the safety profile was comparable to that of Entresto. In conclusion, the obtained results indicate that the use of Savesto can be considered as a rational and affordable alternative to the original drug in patients with heart failure with reduced ejection fraction and type 2 diabetes mellitus, while maintaining proven therapeutic value and safety.

Maqola ma’lumotlari
MualliflarФайзуллаев Бахром Рустамович, Исломов Иномжон Исломович, Хусаинов Адхам Шухратович, Норматова Умида Юлдашевна
JurnalМарказий Осиё эндокринологик журнали
NashriyotРеспублика ихтисослаштирилган эндокринология илмий-амалий тиббиёт маркази
ISSN2181-3426
Nashr sanasi2026-06-27
Jild6
Son2
TilIngliz
Ilmiy sohaTibbiyot
Indeksga qo‘shilgan2026-08-26

Maqolaning asl sahifasi

Kalit so‘zlar

сердечная недостаточность, острая декомпенсация сердечной недостаточности, сакубитрил/валсартан (Савесто), сахарный диабет 2-типа, хроническая почечная недостаточность, низкая фракция выброса, heart failure, CHF, acute decompensation of heart failure, sacubitril/valsartan (Savesto), type 2 diabetes mellitus, chronic renal failure, low ejection fraction, yurak etishmovchiligi, yurak etishmovchiligining o'tkir dekompensatsiyasi, sakubitril/valsartan (Savesto), 2-toifa diabet, surunkali buyrak etishmovchiligi, past otish fraktsiyasi

Ilmiy soha

Tibbiyot

Iqtibos keltirish

APAФайзуллаев Бахром Рустамович, Исломов Иномжон Исломович, Хусаинов Адхам Шухратович, & Норматова Умида Юлдашевна (2026). TREATMENT OF CHRONIC HEART FAILURE WITH A LOW EJECTION FRACTION WITH SACUBITRIL/VALSARTAN (SAVESTO) ON THE BACKGROUND OF DIABETES MELLITUS TYPE 2. Марказий Осиё эндокринологик журнали, 6(2). https://www.tadqiqot.uz/index.php/cae/article/view/14393
GOST (OAK)Файзуллаев Бахром Рустамович va b. TREATMENT OF CHRONIC HEART FAILURE WITH A LOW EJECTION FRACTION WITH SACUBITRIL/VALSARTAN (SAVESTO) ON THE BACKGROUND OF DIABETES MELLITUS TYPE 2 // Марказий Осиё эндокринологик журнали. – 2026. – T. 6, № 2.
MLAФайзуллаев Бахром Рустамович, Исломов Иномжон Исломович, Хусаинов Адхам Шухратович, and Норматова Умида Юлдашевна. “TREATMENT OF CHRONIC HEART FAILURE WITH A LOW EJECTION FRACTION WITH SACUBITRIL/VALSARTAN (SAVESTO) ON THE BACKGROUND OF DIABETES MELLITUS TYPE 2.” Марказий Осиё эндокринологик журнали, 6(2), 2026. https://www.tadqiqot.uz/index.php/cae/article/view/14393
ChicagoФайзуллаев Бахром Рустамович, Исломов Иномжон Исломович, Хусаинов Адхам Шухратович, and Норматова Умида Юлдашевна. “TREATMENT OF CHRONIC HEART FAILURE WITH A LOW EJECTION FRACTION WITH SACUBITRIL/VALSARTAN (SAVESTO) ON THE BACKGROUND OF DIABETES MELLITUS TYPE 2.” Марказий Осиё эндокринологик журнали, 6(2) (2026). https://www.tadqiqot.uz/index.php/cae/article/view/14393
HarvardФайзуллаев Бахром Рустамович, Исломов Иномжон Исломович, Хусаинов Адхам Шухратович, and Норматова Умида Юлдашевна (2026) ‘TREATMENT OF CHRONIC HEART FAILURE WITH A LOW EJECTION FRACTION WITH SACUBITRIL/VALSARTAN (SAVESTO) ON THE BACKGROUND OF DIABETES MELLITUS TYPE 2’, Марказий Осиё эндокринологик журнали, 6(2). https://www.tadqiqot.uz/index.php/cae/article/view/14393
BibTeX
@article{article2026,
  title = {TREATMENT OF CHRONIC HEART FAILURE WITH A LOW EJECTION FRACTION WITH SACUBITRIL/VALSARTAN (SAVESTO) ON THE BACKGROUND OF DIABETES MELLITUS TYPE 2},
  author = {Файзуллаев Бахром Рустамович and Исломов Иномжон Исломович and Хусаинов Адхам Шухратович and Норматова Умида Юлдашевна},
  journal = {Марказий Осиё эндокринологик журнали},
  year = {2026},
  volume = {6},
  number = {2},
  url = {https://www.tadqiqot.uz/index.php/cae/article/view/14393}
}

Boshqa maqola uchun iqtibos tayyorlash

Марказий Осиё эндокринологик журнали jurnalidan boshqa maqolalar

Марказий Осиё эндокринологик журнали — barcha maqolalar · 2026-yil arxivi

Файзуллаев Бахром Рустамович — boshqa maqolalari

Tibbiyot sohasidagi boshqa maqolalar

Tibbiyot sohasidagi OAK jurnallari